Is Moleculin Biotech, Inc. (MBRX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 7.5% / 30% | 66.8% / 30% | 0.3% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 7.5% / 33% | 66.8% / 33% | 0.3% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 2.8% / 33% | 25.3% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| S&P | 7.5% / 33% | 66.8% / 33% | 0.3% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 2.8% / 33% | 25.3% / 33% | 0.1% / 50% | N/A | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -256.0% | |
| Return on Assets (ROA) | -80.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$24M |
| Free Cash Flow | -$24M |
| Total Debt | $478,000 |
| Debt-to-Equity | 2.4 |
| Current Ratio | 1.4 |
| Total Assets | $17M |
Price & Trading
| Last Close | $2.43 |
| 50-Day MA | $3.22 |
| 200-Day MA | $9.04 |
| Avg Volume | 180K |
| Beta | 1.7 |
|
52-Week Range
$1.79
| |
About Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Moleculin Biotech, Inc. (MBRX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Moleculin Biotech, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Moleculin Biotech, Inc.'s debt ratio?
Moleculin Biotech, Inc.'s debt ratio is 7.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.8%.
What are Moleculin Biotech, Inc.'s key financial metrics?
Moleculin Biotech, Inc. has a market capitalization of $13M. Return on equity stands at -256.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.